Roche bullish on its diagnostics biz

The heads of Roche's ($RHHBY) diagnostics arm aren't worried about CMS reimbursement reductions, saying they are being offset by higher testing volumes. Most Big Pharma companies view diagnostics through the realm of companion diagnostics, but Roche has made the business one of its core competencies. (Just in case, don't expect the division to be sold off as part of the industry's continuing trend toward the streamlining of companies' business units.) Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.